Lederman E D, Conti D J, Lempert N, Singh T P, Lee E C
Department of Surgery, Albany Medical College, New York, USA.
Dis Colon Rectum. 1998 May;41(5):613-8. doi: 10.1007/BF02235270.
Colonic perforations in renal transplant recipients have historically been associated with mortality rates as high as 50 to 100 percent. However, these previous series generally predate the use of cyclosporine-based immunosuppressive protocols.
We retrospectively reviewed all patients who had undergone renal transplant from our institution and who developed complicated diverticulitis. Complicated diverticulitis was defined as diverticulitis involving free perforation, abscess, phlegmon, or fistula. Factors analyzed included the time interval since transplantation, use of cyclosporine, living-related vs. cadaveric donor, cause of renal failure, and presenting signs and symptoms.
Between August 1969 and September 1996, 1,211 kidney transplants were performed in 1,137 patients. The first 388 patients (1969-1984) received prednisone and azathioprine, with cyclosporine added to the immunosuppressive regimen for the subsequent 823 recipients (1984-1996). Thirteen (1.1 percent) patients had episodes of complicated diverticulitis, occurring from 25 days to 14 years after transplant; all required surgical therapy. Clinical presentation was highly variable, ranging from asymptomatic pneumoperitoneum (2 patients) to generalized peritonitis. There was one perioperative mortality (7.7 percent). Patients with polycystic kidney disease as the cause of renal failure had a significantly higher rate of complicated diverticulitis. Specifically, patients with polycystic kidney disease (9 percent of the total transplant population) accounted for 46 percent of the cases of diverticulitis (P < 0.001, Fisher's exact probability test). Neither treatment with cyclosporine nor donor source had a significant effect on the rate of diverticular complications (P = 0.36 and P = 0.99, respectively, Fisher's exact probability test).
Complicated diverticulitis following renal transplantation is rare, and the clinical presentation may be atypical in the immunosuppressed transplant recipient. Patients with polycystic kidney disease experience a significantly higher rate of complicated diverticulitis than do other transplant patients and, therefore, warrant aggressive diagnostic evaluation of even vague abdominal symptoms. In addition, pretransplant screening and prophylactic sigmoid resection in this high-risk population deserve consideration and further study.
肾移植受者发生结肠穿孔,在历史上其死亡率高达50%至100%。然而,这些既往系列研究大多早于基于环孢素的免疫抑制方案的应用。
我们回顾性分析了我院所有接受肾移植且发生复杂性憩室炎的患者。复杂性憩室炎定义为伴有游离穿孔、脓肿、蜂窝织炎或瘘管的憩室炎。分析的因素包括移植后的时间间隔、环孢素的使用、活体亲属供体与尸体供体、肾衰竭病因以及临床表现和症状。
1969年8月至1996年9月,1137例患者接受了1211例肾移植。前388例患者(1969 - 1984年)接受泼尼松和硫唑嘌呤治疗,随后的823例受者(1984 - 1996年)在免疫抑制方案中加用了环孢素。13例(1.1%)患者发生复杂性憩室炎,发生于移植后25天至14年;均需手术治疗。临床表现差异很大,从无症状气腹(2例患者)到弥漫性腹膜炎。围手术期死亡1例(7.7%)。以多囊肾病作为肾衰竭病因的患者发生复杂性憩室炎的比例显著更高。具体而言,多囊肾病患者(占移植总人群的9%)占憩室炎病例的46%(P < 0.001,Fisher精确概率检验)。环孢素治疗和供体来源对憩室并发症发生率均无显著影响(分别为P = 0.36和P = 0.99,Fisher精确概率检验)。
肾移植后发生复杂性憩室炎很罕见,在免疫抑制的移植受者中临床表现可能不典型。多囊肾病患者发生复杂性憩室炎的比例显著高于其他移植患者,因此,即使是模糊的腹部症状也需要积极进行诊断评估。此外,对于这一高危人群,移植前筛查和预防性乙状结肠切除术值得考虑并进一步研究。